EMEA-003522-PIP01-23 - paediatric investigation plan
Zanzalintinib
PIPHuman
Key facts
- Active Substance
- Zanzalintinib
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0050/2024
- PIP number
- EMEA-003522-PIP01-23
- Pharmaceutical form(s)
- Film-coated tablet
- Condition(s) / indication(s)
- Treatment of colorectal cancer
- Treatment of head and neck epithelial malignant neoplasms
- Treatment of renal cell carcinoma (RCC)
- Route(s) of administration
- Oral use
- Contact for public enquiries
Exelixis Inc.
Email: druginfo@exelixis.com
Tel. +1 6508377400
- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date